Featured Research

from universities, journals, and other organizations

Carvedilol Is Effective In Preventing Variceal Bleeding In Cirrhotic Patients, Study Suggests

Date:
August 19, 2009
Source:
Wiley-Blackwell
Summary:
In a recent study, researchers determined carvedilol was more effective in the prevention of variceal hemorrhaging than variceal band ligation, a common treatment used for the past 20 years.

Patients with cirrhosis are at risk for developing portal hypertension that can lead to the formation, dilation, and rupture of esophageal varices. The annual incidence of esophageal varices is approximately 5% and one third of those will bleed.

Related Articles


In a recent study, researchers from the University of Edinburgh determined carvedilol was more effective in the prevention of variceal hemorrhaging than variceal band ligation (VBL), a common treatment used for the past 20 years. The results of the first clinical trial to test carvedilol for prevention of variceal hemorrhage are available in Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

Dhiraj Tripathi and colleagues at the Royal Infirmary of Edinburgh enlisted 152 cirrhotic patients with grade II or larger esophageal varices that had not bled in this study. Researchers treated 77 patients with carvedilol, a non-cardioselective beta-blocker (NSBB) marketed under the trade name Eucardic (Roche), while 75 patients underwent VBL every two weeks until eradication. Patients were administered carvedilol orally at a starting dose of 6.25 mg per day, increasing to a target dose of 12.5 mg per day.

Results showed 10% of patients receiving carvedilol and 23% of patients treated by VBL experienced variceal bleeding during the follow-up period. There was no difference in survival rates between the two groups. "The greater efficacy of carvedilol in the prevention of the first variceal bleed is an important finding of this study," said Dr. Tripathi. "No other randomized trial has demonstrated drug therapy to have an advantage over VBL."

While researchers concluded carvedilol had greater effectiveness in treating portal hypertension than endoscopic therapy, there were limitations to their study. "Measurements of hepatic venous-pressure gradient (HVPG) were not included as part of the study, making it difficult to determine if the benefit of carvedilol was due to a greater HVPG response or failure of the VBL, noted Dr. Jaime Bosch of the Hepatic Hemodynamic Laboratory Hospital Clinic in Barcelona, Spain in his editorial published in the September issue of Hepatology. HVPG is a standard measure used to determine portal vein pressure with variceal bleeding occurring at gradients of + 12 mm HG.

Propranolol, another NSBB drug commonly used to treat portal hypertension, was not included as part of this study. "Further studies are required to assess whether carvedilol is a better option than standard NSBB," added Dr. Bosch.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Tripathi et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology, 2009; DOI: 10.1002/hep.23045

Cite This Page:

Wiley-Blackwell. "Carvedilol Is Effective In Preventing Variceal Bleeding In Cirrhotic Patients, Study Suggests." ScienceDaily. ScienceDaily, 19 August 2009. <www.sciencedaily.com/releases/2009/08/090819110040.htm>.
Wiley-Blackwell. (2009, August 19). Carvedilol Is Effective In Preventing Variceal Bleeding In Cirrhotic Patients, Study Suggests. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2009/08/090819110040.htm
Wiley-Blackwell. "Carvedilol Is Effective In Preventing Variceal Bleeding In Cirrhotic Patients, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2009/08/090819110040.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins